New PET scan may reveal prostate Cancer's secret spread
NCT ID NCT04655365
First seen Dec 26, 2025 · Last updated Jun 23, 2026 · Updated 23 times
Summary
This study looks at whether a special PET/CT scan (called 18F-DCFPyL) can find cancer spread that standard scans miss in men with castration-resistant prostate cancer starting enzalutamide. Fifty men whose standard scans showed no or few metastases will get the new scan. The goal is to see how often the new scan finds hidden tumors and how they change over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU de Québec-Université Laval
Québec, Quebec, Canada
-
CHUM
Montreal, Quebec, H2X 0A9, Canada
-
CIUSSS de l'Estrie - CHUS
Sherbrooke, Quebec, J1J 3H5, Canada
-
CUSM
Montreal, Quebec, H3H 2R9,, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-DCFPyL (a radioactive tracer for PET/CT scans) and enzalutamide (a hormone therapy drug)
What this could lead to
If successful, this could show that PSMA PET/CT scans are more accurate at finding hidden cancer spread, helping doctors choose better treatments.
What could go wrong
This is a small, early-phase study (50 people) focused on imaging accuracy, not on curing or controlling the cancer. The scan may not change patient outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.